Company Alignment on Long-term Strategic Agenda and Investment on Operation and Execution
MONTEVIDEO, Uruguay, March 22, 2019 /PRNewswire/ -- Biotoscana Investments S.A. (GBIO33.SA), a biopharmaceutical group that operates in Latin America, announced today its results for the 4Q18 and 2018.
Net revenues for 2018 increased by 10% in constant currency, positively impacted by Dosa, marking BRL 821M (including hyperinflation adjustment).
Gross profit increased by 12% vs. 2017, in constant currency. Gross margin of 51% (including hyperinflation adjustments) vs. 54% in 2017.
OPEX are in line with 34% of net revenues in 2018.
Adjusted EBITDA increased by 12% in constant currency vs. 2017. Adjusted EBITDA margin came to 22% in 2018 (including hyperinflation adjustment), vs. 24% in 2017.
Net income totaled BRL 63M in 2018 (including hyperinflation adjustment) vs. BRL 17M in 2017. Adjusted net income up 42% vs. 2017, in constant currency.
Strategic agenda evolved with the ongoing execution of the pipeline.
Recently launched products growing over 100%, with the performance of new products such as LENVIMA, ABRAXANE and Gilead portfolio.
+55 11 5090-5927.